Medication-Assisted Treatment

Medications for addiction treatment remain dramatically underutilized despite decades of evidence, with fewer than a quarter of patients with OUD receiving buprenorphine, methadone, or naltrexone. This track focuses on implementation science: emergency department buprenorphine initiation (the CA Bridge model), low-threshold telehealth prescribing protected by the post-COVID DEA flexibilities, jail and prison MOUD per the 2024 DOJ ADA guidance, and integration into primary care, OB, and HIV clinics. Sessions will address provider stigma, the elimination of the X-waiver under MAT Act, and pay-for-performance and bundled-payment models accelerating MAT scale-up.